WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
Overview
Zen RatingPriceValueGrowthFinancialsMomentumSentimentForecastDividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the 3rd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Exchange
Industry
Zen Rating
Market Cap
Price
1d %
EBITDA
P/E
D/E
Country
DD Score
GSK
GSK PLC
NYSE
Drug Manufacturers - General
$95.18B$47.192.34%$10.28B13.08x2.82
United Kingdom
MRK
MERCK & CO INC
NYSE
Drug Manufacturers - General
$242.64B$97.762.94%$27.65B12.91x1.50
United States
BMY
BRISTOL MYERS SQUIBB CO
NYSE
Drug Manufacturers - General
$94.15B$46.250.67%$12.94B15.57x4.22
United States
LLY
ELI LILLY & CO
NYSE
Drug Manufacturers - General
$1.00T$1,059.701.57%$24.40B51.72x3.83
United States
GRFS
GRIFOLS SA
NASDAQ
Drug Manufacturers - General
$5.78B$8.40-0.36%$1.71B32.81x2.18
United States
GILD
GILEAD SCIENCES INC
NASDAQ
Drug Manufacturers - General
$157.12B$126.641.32%$13.67B19.45x1.72
United States
AMRN
AMARIN CORP PLC
NASDAQ
Drug Manufacturers - General
$340.58M$16.38-0.30%-$80.28M-3.90x0.44
Ireland
ABBV
ABBVIE INC
NYSE
Drug Manufacturers - General
$417.60B$236.282.98%$12.49B177.65x-51.66
United States
AMGN
AMGEN INC
NASDAQ
Drug Manufacturers - General
$181.76B$337.540.44%$16.53B25.90x8.37
United States
JNJ
JOHNSON & JOHNSON
NYSE
Drug Manufacturers - General
$491.26B$203.900.41%$39.78B19.55x1.43
United States
AZN
ASTRAZENECA PLC
NASDAQ
Drug Manufacturers - General
$282.10B$91.002.62%$19.64B29.98x1.49
United Kingdom
SNY
SANOFI
NASDAQ
Drug Manufacturers - General
$125.38B$49.631.51%$18.05B11.43x0.78
France
NVS
NOVARTIS AG
NYSE
Drug Manufacturers - General
$245.20B$127.312.37%$28.18B17.27x1.41
Switzerland
OGN
ORGANON & CO
NYSE
Drug Manufacturers - General
$1.87B$7.200.98%$1.56B3.73x13.96
United States
SCLX
SCILEX HOLDING CO
NASDAQ
Drug Manufacturers - General
$170.75M$22.5118.79%-$319.06M-0.71x-2.54
United States
PFE
PFIZER INC
NYSE
Drug Manufacturers - General
$142.37B$25.042.62%$15.84B14.56x1.25
United States
BIIB
BIOGEN INC
NASDAQ
Drug Manufacturers - General
$25.72B$175.304.23%$2.71B15.95x0.60
United States
MIRA
MIRA PHARMACEUTICALS INC
NASDAQ
Drug Manufacturers - General
$58.21M$1.392.96%-$5.60M-0.53x0.01
United States
MDCX
MEDICUS PHARMA LTD
NASDAQ
Drug Manufacturers - General
$46.92M$2.134.41%-$29.72M-0.99x-11.85
United States
NSRX
NASUS PHARMA LTD
NYSEMKT
Drug Manufacturers - General
N/A$7.253.57%-$1.50M-32.95x-1.22
Israel
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Nov 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -4 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 40.03% over the past year, overperforming other general drug manufacturer stocks by 13 percentage points.

2. Merck & Co (NYSE:MRK)


Merck & Co (NYSE:MRK) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Merck & Co (NYSE:MRK) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: A, and AI: C.

Merck & Co (NYSE:MRK) has a Due Diligence Score of 55, which is 15 points higher than the general drug manufacturer industry average of 40.

MRK passed 20 out of 38 due diligence checks and has strong fundamentals. Merck & Co has seen its stock lose -2.1% over the past year, underperforming other general drug manufacturer stocks by -30 percentage points.

Merck & Co has an average 1 year price target of $97.20, a downside of -0.57% from Merck & Co's current stock price of $97.76.

Merck & Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 5 analysts covering Merck & Co, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 12 points higher than the general drug manufacturer industry average of 40.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -20.57% over the past year, underperforming other general drug manufacturer stocks by -48 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $39.50, a downside of -14.59% from Bristol Myers Squibb Co's current stock price of $46.25.

Bristol Myers Squibb Co stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Bristol Myers Squibb Co, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.46%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.79%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

2. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) has an annual dividend yield of 4.44%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.79%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 3.55%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.79%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 45.6% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 1.86% in the last day, and up 2.3% over the last week. Merck & Co was the among the top gainers in the drug manufacturers - general industry, gaining 2.94% yesterday.

Merck shares are trading higher after the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -51.65% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -79 percentage points.

2. Merck & Co (NYSE:MRK)


Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 43, which is 4 points higher than the general drug manufacturer industry average of 39. It passed 3 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -2.1% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -30 percentage points.

3. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 10.94% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -16 percentage points.

Are general drug manufacturer stocks a good buy now?

37.5% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 0.57% over the next year.

42.11% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 21.05% of general drug manufacturer stocks are rated B (Buy), 26.32% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 47.29x.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.